Stella Gaenger

发表

Clonal Evolution in Patients with Hormone Receptor Positive, HER-2 Negative Breast Cancer Treated with Chemotherapy or CDK4/6 Inhibitors

T. Decker, K. Geiger, T. Dechow, 2022, Oncology Research and Treatment.

Data on the association of serum glypican-4 with future major adverse cardiovascular events and mortality in patients undergoing coronary angiography

P. Fraunberger, K. Geiger, A. Leiherer, 2022, Data in brief.

Serum glypican-4 is associated with the 10-year clinical outcome of patients with peripheral artery disease.

P. Fraunberger, K. Geiger, A. Leiherer, 2022, International journal of cardiology.

Evaluation of the association of serum glypican-4 with prevalent and future kidney function

P. Fraunberger, K. Geiger, D. Haider, 2022, Scientific Reports.

Serum glypican-4 is a marker of future vascular risk and mortality in coronary angiography patients.

P. Fraunberger, K. Geiger, A. Leiherer, 2022, Atherosclerosis.

Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients

W. Jagla, A. Gaumann, T. Decker, 2021, Scientific Reports.

Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients

T. Decker, T. Winder, K. Geiger, 2023, Journal of Cancer Research and Clinical Oncology.

Coronary Event Risk Test (CERT) as a Risk Predictor for the 10-Year Clinical Outcome of Patients with Peripheral Artery Disease

R. Laaksonen, P. Fraunberger, K. Geiger, 2023, Journal of Clinical Medicine.

Circulating glypican-4 is a new predictor of all-cause mortality in patients with heart failure.

P. Fraunberger, K. Geiger, C. Heinzle, 2023, Clinical biochemistry.

Myricetin attenuates hypoxia-induced inflammation in human adipocytes

P. Fraunberger, K. Geiger, E. Brandtner, 2023, Molecular Biology Reports.